During the third quarter, GDS Wealth Management reduced its UnitedHealth Group stake by 10.7%, selling 5,297 shares and ending the period with 44,252 shares valued at approximately $15.28 million. Cullen Frost Bankers Inc. also trimmed its position by 27.1%, offloading 29,527 shares for a remaining holding of 79,459 shares worth about $27.44 million. Smaller allocators were active as well: LFA Lugano Financial Advisors initiated a position valued near $25,000, Sagard Holdings added roughly $29,000, Grey Fox Wealth Advisors invested around $33,000, and Islay Capital Management deployed about $31,000 during the same quarter. Hedge funds and institutional investors collectively own 87.86% of the company’s stock, underscoring broad professional confidence despite recent reallocations.

UnitedHealth Group reported third‐quarter earnings per share of $2.92, surpassing consensus estimates by $0.05, on revenue of $113.16 billion, essentially in line with projections. Year‐over‐year revenue rose 12.2%, while net margin stood at 4.04% and return on equity reached 19.23%. The company maintained a debt‐to‐equity ratio of 0.71 and both current and quick ratios at 0.82, reflecting a balanced liquidity profile. On a full‐year basis, analysts forecast earnings per share of approximately 29.54, driven by sustained growth in both UnitedHealthcare and Optum segments.

Wall Street sentiment remains positive, with one analyst assigning a Strong Buy rating, seventeen Buys and nine Holds, culminating in a consensus Moderate Buy. Recent target adjustments include Jefferies raising its objective from $317 to $409, UBS boosting its target to $430, and Piper Sandler setting an Overweight stance. UnitedHealth Group declared a quarterly dividend of $2.21 per share, paid December 16 to holders of record as of December 8, implying an annualized payout of $8.84 and a payout ratio of 46.14%. Investors are watching forthcoming guidance and the Medicare Advantage 2027 Advance Notice for potential catalysts to enrollment and margin expansion.